anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To efficiently produce a medicinal preparation of uniformly fine particles. SOLUTION: A medicinal preparation having a medicinal layer on the outside of the core particles is prepared. A medicine is crushed with a jet crusher or the like to give particles with an average particle size of 1-20μm. The particles are combined with a binder such as hydroxypropylcellulose and purified water to dissolve or disperse them thereby giving a coating solution. The core particles are coated with this coating solution to effect the coating granulation whereby a medicinal preparation of uniformly fine particles is obtained. The core particles are made from Celphere (R) nonpareil, lactose, sucrose and the like, while the medicine is, for example, bisibutiamine, riboflavin, anhydrous caffeine, theophylline, aspirin, dextromethorphan hydrobromide, acetaminophen, ibuprofen, sofalcone, clarithromycin and the like.  The amount of the medicine in the coating solution is 1-45wt.% while the amount of the binder in the coating solution is 1-25wt.%.
This is a single cohort, exploratory pilot study of 60 participants to assess if ovarian cancer markers, cancer antigen-125 (CA-125) and human epididymis protein 4 (HE4), are measurable from cul-de-sac washings collected via culdocentesis. Immediately prior to the scheduled surgery, while the patient is under general anesthesia, a long, thin needle will be inserted through the wall of the vagina (just below the uterus) to access the cul-de-sac. A saline wash will then be performed and this fluid will be collected for analysis of tumor markers. CA-125 and HE4 levels will be compared to serum levels for correlation with a diagnosis of ovarian cancer. A urine sample will also be collected from this same cohort to measure estrogen metabolites. Estrogen metabolism is associated with cancer progression in estrogen sensitive tissues. Estrogen metabolites, 2-hydroxyestrone (2-OHE1) the "good" byproduct and 16α-hydroxyestrone (16α-OHE1) known as the "bad" byproduct, have been implicated in the development of breast cancer. Study investigators are proposing to expand the utility of this predictive ratio to ovarian cancer by measuring the potential imbalance of these metabolites.

If results indicate an association between cancer diagnosis and levels of CA-125 and HE4 or the ratio of estrogen metabolites from the urine, this could allow for a new minimally invasive, low-risk diagnostic modality for all suspected ovarian cancer cases. This would be particularly invaluable for patients at higher risk for poor surgical outcomes. Data from this pilot study will confirm the potential effect size needed to identify an optimal cut-point useful for the prediction of EOC within this study population.
Background: High-flow nasal cannula (HFNC) is a device that can reduce the work of breathing (WOB) and improve oxygenation by providing a flow that matches or exceeds patient's peak inspiratory flow during tidal breathing. Despite its widespread use, there remains a lack of consensus regarding the optimal flow settings. Two new HFNC devices that can provide information regarding patient's peak tidal inspiratory flow breath by breath are recently available, which might help guide set and titrate the flow settings. This study aims to investigate the effects of different flow settings on lung impedance in a cohort of healthy volunteers by using the two new HFNC devices.

Methods: This prospective, randomized crossover trial will enroll adult healthy volunteers. Initially, the subject's peak inspiratory flow will be measured using a mask connected with a respiratory monitor. Subsequently, the volunteers will undergo HFNC treatment at different flow settings while their peak inspiratory flow will be continuously monitored. The primary outcome of this study is the lung aeration with different flow settings. Secondary outcomes include the lung aeration with different devices, subject's comfort at different flow settings, and the correlation between the subject's peak inspiratory flow measured by HFNC and by a mask connected with a respiratory monitor.
Community mental health centers (CMHCs) play a pivotal role in the provision of comprehensive care and support for individuals with mental health challenges. However, these centers often face formidable obstacles, including surging patient demands, lengthy waiting lists, high dropout rates, and barriers to engagement, stigma, and negative attitudes. Given these challenges, there exists an urgent imperative to develop innovative interventions that can enhance treatment satisfaction, patient activation, knowledge, and patient engagement, and ultimately yield improved mental health outcomes. One promising approach for addressing these challenges lies in the realm of patient engagement and enablement strategies, particularly through the implementation of digital educational interventions.

The investigators hypothesize that utilizing innovative technology to deliver an early digital self-management educational program improves treatment satisfaction, patient activation, knowledge, patient engagement, and overall mental health outcomes without substantially increasing service costs. The impact of utilizing innovative technology to deliver an early digital pre-therapy patient education program through the HelsaMi web patient portal is promising. By leveraging technology, it is possible to reach a wider audience and provide accessible and convenient information, with the same standard to all patients. This approach has the potential to improve patient outcomes, increase treatment adherence, and reduce the burden on healthcare resources. By demonstrating the benefits of digital interventions, our research will pave the way for more efficient and cost-effective mental healthcare services, benefiting both patients and healthcare systems.
The present invention relates to a new usage purpose of Leoidin compound, and specifically, to a pharmaceutical composition for treating or preventing bacterium infection, including Leoidin compound having antitoxic or antivirulence activity, a derivative thereof, or pharmaceutically allowable salt of the same. According to the present invention, the Leoidin or the derivative thereof does not influence growth of bacteria but can suppress hemolytic action of red blood cells due to the bacteria. Also, the Leoidin or the derivative thereof can suppress revelation of various toxic genes by suppressing the revelation of sae and sarA modulators. Also, the Leoidin or the derivative thereof can suppress bacteria internalization by suppressing adhesion and/or infiltration of the bacteria to a host cell. Also, the Leoidin or the derivative thereof does not cause any toxicity to the host cell and can be easily used for manufacture of food or feed additives, feed for an animal, health food, a cosmetic compound, and a medicine for preventing, improving, or treating the bacteria infection. Also, the Leoidin or the derivative thereof can be usefully used to clean a medical container or to suppress the bacteria having the toxicity or a tolerance to antibiotics.
The increased prevalence of obesity in both the developed and developing worlds paved the way to the increased prevalence of yet another obesity-related complication significant enough to be considered within the roster of major public health threats: non-alcoholic fatty liver disease (NAFLD). It has been estimated that approximately 20% to 30% of the adult population harbors NAFLD. It is also the most common liver pathology among children of developed countries. Unfortunately, despite the alarming figures, NAFLD remains largely underdiagnosed, probably because of its less aggressive nature and benign presentation compared with other liver diseases. Thus, it is apparent that NAFLD, being a precursor to more serious liver conditions such as cirrhosis and hepatocellular carcinoma, should be given equal, if not greater, clinical significance.

Accumulating evidence has pointed to parallel clinical similarities between NAFLD and metabolic syndrome (MetS), the clustering of cardiovascular risk factors with insulin resistance as the common unifying factor. It is well established that persons with MetS are at greater risk of progressing to major chronic non-communicable diseases such as coronary artery disease and type 2 diabetes mellitus (T2DM). Consequently, patients with T2DM are more likely to develop NAFLD. Obesity is acknowledged as one of the common denominators linking NAFLD, MetS, and T2DM, making dietary and lifestyle modifications the gold standard for the treatment of these clinical entities aside from pharmacotherapy that aims to improve insulin sensitivity. Therefore, it is important to better understand the intricate pathophysiology of NAFLD among patients with T2DM so that future interventions will be aimed at reversing complications.

Our current knowledge of NAFLD in terms of prognosis and treatment is promising yet inconclusive, which means that further investigations using prospective approaches are required. Only recently was a consensus design for clinical trials and endpoints for non-alcoholic steatohepatitis (NASH) reported. In this follow-up study, the investigators attempt to decipher the natural history of hepatic steatosis among patients with T2DM using state-of-the-art methods in a well-characterized Saudi cohort. Diabetes, and its related medical complications, have been identified as one of the priority areas of the National Plan for Science and Technology in the Kingdom of Saudi Arabia (KSA).
Participants will be recruited after they have been diagnosed and their treatment has been planned by a multidisciplinary tumor board. Patients indicated to undergo major liver resection (\> 3 segments based on Brisbane classification \[23\]) will be eligible for participation.
A polymerizable power-liquid composition suitable for the production of dental prostheses contains a bead polymer, a liquid monomer containing methyl methacrylate and an acrylate or methacrylate ester having at least one OH group in its alcohol radical, and 0.2 to 20%, by weight of liquid monomer, of an ethylenically unsaturated polymerizable carboxylic acid or an anhydride thereof.  Suitable hydroxy - ester monomers include hydroxyalkyl (meth)acrylates in which the alkyl group has up to 6 carbon atoms, and glycerol mono(meth)acrylate; suitable acid monomers include acrylic, methacrylic, maleic and itaconic acids and their anhydrides. The liquid monomer may also include a cross-linking monomer, e.g. the dimethacrylate of ethylene or butylene glycol. The bead polymer is preferably a homopolymer or copolymer of methyl methacrylate, e.g. with a comonomer such as an acrylate or methacrylate ester or butadiene; or a mixture of such polymers. The composition may include the usual resin, plasticizer or dyestuff additives, and is generally cured in a mould using a catalyst such as benzoyl peroxide.
Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
Febrile conditions often have an infectious etiology. However, there are also fevers associated with occupational exposures. A detailed occupational history can hold the key to the diagnosis. In the case of exposure to organic dusts, the development of hypersensitivity pneumonitis (HP) is possible. Thus, HP should be considered in the presence of interstitial lung disease of unclear etiology. Failure to recognize this can have dramatic consequences and, in extreme cases, lead to lung transplantation. Differentially, organic dust toxic syndrome (ODTS) must be considered. The syndrome of metal fume fever provoked by inhalation of inorganic substances is usually benign and self-limiting. The disease manifests with fever, cough, and flu-like sensations.
The present invention refers to a plurality of compositions of antibacterial geopolymers and the manufacturing method thereof. Said plurality of antibacterial geopolymers is limited by the molar relationships of the different silicon, aluminium oxides, alkaline metals and water, as well as by the used ranges of the bactericide and/or fungicide agents or materials herein described. The antibacterial geopolymers are inorganic materials with amorphous to semi-crystalline structure, which inhibit the development, reproduction or existence of bacteria, yeast and fungi. The compositions are materials with bactericide and/or fungicide properties useful for the development and/or manufacture of antibacterial ceramic materials, mortars, concretes and coatings, which may be applied in the industry in general, being substantially useful in the construction, architectonic and decoration industry, also being applied in clinics, hospitals, medical offices, nurseries, food preparation and handle are as, and in areas of personal hygiene such as bathrooms, tubs, sinks, knobs, etc. And where an antibacterial and/or antifungal protection is required. In addition, the present invention is highly resistant to fire, presenting a high chemical resistance to diverse compounds and organic solvents. This material has adhesive or binding properties at the moment of being manufactured, thus may be used as an inorganic antibacterial cement and may be adhered to metallic, ceramic, glass and composite surfaces for generating antibacterial and/or antifungal surfaces. An other advantage of the antibacterial geopolymers is that are obtained at a room temperature or temperatures under 300 °C, thereby substantially reducing the production costs in the industry and also presenting a pleasing aesthetic appearance, similar to those found in rocks and minerals of natural origin but with an antibacterial and/or antifungal benefit.
Fibrosis results from the excessive production of extracellular matrix proteins by myofibroblasts. It has recently been reported that in the heart, myofibroblasts develop chondrocyte-like properties following myocardial infarction as fibrosis progresses and tissues stiffen. However, the nature of these chondrocyte-like myofibroblasts remains unclear. In this study, we found that the expression of the proline- and arginine-rich end leucine-rich repeat protein (PRELP) was upregulated in hearts and livers stiffened by fibrosis with chronic inflammation. Moreover, we established that Prelp was specifically expressed in chondrocyte-like myofibroblasts. Prelp expression was found to be regulated by the transcription factor SOX9, and in cardiac and liver myofibroblasts, Prelp-knockdown was observed to reduce collagen expression. These findings reveal that PRELP is specifically expressed in chondrocyte-like myofibroblasts and that it promotes collagen production. PRELP could thus serve as a novel therapeutic target for treating fibrosis.
The main purpose of this study was to evaluate the value of two telerehabilitation exercise programs for treating multidirectional shoulder instability (MDI) in patients diagnosed with the hypermobile type of The Ehlers-Danlos syndrome (hEDS) or Hypermobility Spectrum Disorders (HSD). Patients were randomly assigned to either the control group (B: evidence-based tailored care) or the experimental group (A: evidence-based standard care). Both groups received a home-based exercise program of 24 weeks. The primary outcome measure was the Western Ontario Shoulder Index (WOSI). Secondary outcomes included the Disabilities of the Arm, Shoulder and Hand (DASH), Tampa Scale for Kinesiophobia (TSK), Patient-Specific Functional Scale (PSFS), Global Rating of Change (GROC), and pain pressure thresholds (PPTs). Outcomes were assessed at baseline, after 6 weeks, 12 weeks, and at the end of the study (24 weeks).
PURPOSE:To obtain readily drinkable cervi cornu SAKE (Japanese rice wine), having tonic, hypotensive, fatigue recovering action, etc., by extracting cervi cornu with an ethyl alcohol-containing extracting liquid, mixing the resultant extract solution with a raw material SAKE (Japanese rice wine), such as SAKE or 'SHOCHU' (low-class distilled spirit with a high content of alcohol), and aging the resultant mixture. CONSTITUTION:A young horn newly growing in spring every year is cut from red deer or Formosan deer, treated with hot water and dried to produce cervi cornu, which is then dipped in an ethyl alcohol-containing extracting liquid to afford a cervi cornu extract solution. The resultant extract solution is subsequently mixed with a raw material SAKE, such as SAKE or 'SHOCHU', and aged for a prescribed time to afford cervi cornu SAKE. Thereby, odor and taste unique to the cervi cornu are moderated by action of the SAKEs, such as SAKE, to make the SAKE readily drinkable. An extract solution of a medicinal herb, such as Zizyphi Inermi Fructus, can be added thereto in a charging step and aged to more rapidly mature the odor of the cervi cornu. Thereby, the cervi cornu SAKE of mellow flavor can be produced.
This is an open-label (the name of the study drug will be known to the healthy volunteers participating in this study as well as to all study staff), randomized (volunteers will be assigned by chance to 1 of 6 possible treatment sequences of a single dose of 3 different capsule formulations of JNJ-39439335) to evaluate the pharmacokinetics (blood levels of drug) and relative bioavailability (i.e., the rate and extent of absorption of the drug in the body) of JNJ-39439335 (Part 1 of the study). The effect of food on the administration of JNJ-39439335 will then be evaluated on 1 capsule formulation of JNJ-39439335 (Part 2 of the study). The safety and tolerability of JNJ-39439335 will be monitored throughout Part 1 and 2 of the study. In Part 1, healthy volunteers will be randomly assigned to 1 of 6 treatment sequences and will receive a total of 3 single doses of JNJ-39439335. Each dose (2 capsules) will be separated by 21 days. In Part 2, healthy volunteers will be randomly assigned to 1 of 2 treatment sequences and will receive a total of 2 single doses of one formulation selected from Part 1; each dose will be separated by 21 days. Doses will be administered to healthy volunteers under fed and fasted conditions.
Participants who are anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab 1050 or 700 mg (dose level 0 \[DL0\]) if BW is \<80 kg, or 1400 or 1050 mg (dose de-escalation \[DL-1\]) if BW is \>= 80 kg, on Days -1, -2, 8 and 22 of Cycle 1 and along with mFOLFOX6 SOC chemotherapy on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days) in Phase 1b dose confirmation Cohort (Cohort Ph1b-D). Participant in Phase 2 Cohort (Cohort D) will receive recommended Phase 2 combination dose (RP2CD) of amivantamab along with mFOLFOX6 SOC chemotherapy determined in Cohort Ph1b-D.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 1-year clinical trial that included 678 postmenopausal women treated with PREMPRO and 351 postmenopausal women treated with PREMPHASE, the following adverse reactions occurred at a rate ≥ 1 percent, see Table 1.

In addition, phargyngitis and sinusitis were reported as two of the more frequent adverse events (>5 percent) in the PREMPRO clinical study. For pharyngitis, of the 121 events, six events were considered by the investigator causally related to study drug. For sinusitis, of the 73 events, one event was considered as casually related to study drug.

During the first year of a 2-year clinical trial with postmenopausal women between 40 and 65 years of age (88 percent Caucasian), 989 postmenopausal women received continuous regimens of PREMPRO, and 332 received placebo tablets. Table 2 summarizes adverse reactions that occurred at a rate ≥ 1 percent in at least 1 treatment group.

In addition, the following events were considered as related to the study drug with an incidence less than 1 percent, including accidental injury, infection, myalgia, cough increased, rhinitis, sinusitis, and upper respiratory infection.
PURPOSE:To improve durable strength and impact absorbing capability by forming the title tool with a crosslinked body prepd. by crosslinking an ethylene-alpha-olefin-diene copolymer. CONSTITUTION:The title tool is formed of a crosslinked body prepd. by crosslinking an ethylene-alpha-olefin-diene copolymer. It is pref. that diene constituting the ethylene-alpha-olefin-diene copolymer be at least either dicyclopentadiene and ethylidene-norbornene. In the crosslinked body of the ethylene-alpha-olefin-diene copolymer, as crosslinks are pruducted between polymers, the crosslinked body exhibits rubbery elasticity and the elasticity is remarkably higher than that of the conventional thermoplastic resin and the durable strength is high. In addition, as a diene has high copolymerizing properties with ethylene-alpha-olefin and crosslinking strength after crosslinking treatment is high, the crosslinked body exhibits high performance.
Human leukocyte antigen (HLA) class I defects are associated with cancer progression. However, their prognostic significance is controversial and may be modulated by immune checkpoints. Here, we investigated whether the checkpoint B7-H3 modulates the relationship between HLA class I and pancreatic ductal adenocarcinoma (PDAC) prognosis. PDAC tumors were analyzed for the expression of B7-H3, HLA class I, HLA class II molecules, and for the presence of tumor-infiltrating immune cells. We observed defective HLA class I and HLA class II expressions in 75% and 59% of PDAC samples, respectively. HLA class I and B7-H3 expression were positively related at mRNA and protein level, potentially because of shared regulation by RELA, a sub-unit of NF-kB. High B7-H3 expression and low CD8+ T cell density were indicators of poor survival, while HLA class I was not. Defective HLA class I expression was associated with unfavorable survival only in patients with low B7-H3 expression. Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.
Omeprazole is an inhibitor of CYP2C19 enzyme. Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Warnings and Precautions (5.6)]. 

In a crossover clinical study, 72 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as clopidogrel) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when clopidogrel and omeprazole were administered together. The active metabolite of clopidogrel selectively and irreversibly inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor, thereby inhibiting platelet aggregation. The mean inhibition of platelet aggregation at 5 mcM ADP was diminished by 39% (Day 1) and 21% (Day 5) when clopidogrel and omeprazole were administered together. 

In another study, 72 healthy subjects were given the same doses of clopidogrel and 80 mg omeprazole but the drugs were administered12 hours apart; the results were similar, indicating that administering clopidogrel and omeprazole at different times does not prevent their interaction [see Warnings and Precautions (5.6)].

There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel.